Wei Zeng1, Liming Cao2, Jinou Zheng3, Lu Yu3. 1. Department of Neurology, Liuzhou People's Hospital, Liuzhou, China. 2. Department of Neurology, The 3rd Affiliated Hospital of Shenzhen University, Shenzhen, China. caolm-2007@163.com. 3. Department of Neurology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Abstract
OBJECTIVE: To analyze the clinical profile and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. METHOD: This is a retrospective, multicenter, self-controlled study of 10 patients with relapsing anti-NMDAR encephalitis. Relapse was defined as new psychiatric or neurologic syndrome unexplainable by other causes that improved after immunotherapy. RESULTS: The main symptoms at first onset and relapse included psychiatric symptoms, cognitive impairment, speech dysfunction, seizures, consciousness disturbance, movement disorders, central hypoventilation, and autonomic dysfunction. There were significantly fewer seizures and consciousness disturbances at relapse. At the first onset, the antibody positivity rate was significantly higher in the cerebrospinal fluid (CSF) than in the serum, and abnormal electroencephalograms results were noted in all patients. The relapse rate was 12.2%. After first-onset discharge, the duration of medication intake was 3.10 ± 2.69 months; the relapse time was 18.3 ± 16.5 months. The Modified Rankin Scale (MRS) score at relapse was significantly lower than that at the first onset. The MRS scores at relapse and first onset after immunotherapy were significantly lower than those before immunotherapy. At follow-up, the average duration of antiepileptic drug (AED) intake was < 1 year; the relapse rate was low. CONCLUSIONS: Patients have fewer symptoms and better quality of life at relapse than at the first onset. Active immunotherapy can significantly improve the quality of life during first onset and relapse. Encephalitis antibody testing in the CSF is preferred at first onset and relapse. Increasing antibody titers suggest clinical relapse. Prematurely stopping immunotherapy may lead to relapse, but prolonged AED intake is unnecessary.
OBJECTIVE: To analyze the clinical profile and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. METHOD: This is a retrospective, multicenter, self-controlled study of 10 patients with relapsing anti-NMDAR encephalitis. Relapse was defined as new psychiatric or neurologic syndrome unexplainable by other causes that improved after immunotherapy. RESULTS: The main symptoms at first onset and relapse included psychiatric symptoms, cognitive impairment, speech dysfunction, seizures, consciousness disturbance, movement disorders, central hypoventilation, and autonomic dysfunction. There were significantly fewer seizures and consciousness disturbances at relapse. At the first onset, the antibody positivity rate was significantly higher in the cerebrospinal fluid (CSF) than in the serum, and abnormal electroencephalograms results were noted in all patients. The relapse rate was 12.2%. After first-onset discharge, the duration of medication intake was 3.10 ± 2.69 months; the relapse time was 18.3 ± 16.5 months. The Modified Rankin Scale (MRS) score at relapse was significantly lower than that at the first onset. The MRS scores at relapse and first onset after immunotherapy were significantly lower than those before immunotherapy. At follow-up, the average duration of antiepileptic drug (AED) intake was < 1 year; the relapse rate was low. CONCLUSIONS:Patients have fewer symptoms and better quality of life at relapse than at the first onset. Active immunotherapy can significantly improve the quality of life during first onset and relapse. Encephalitis antibody testing in the CSF is preferred at first onset and relapse. Increasing antibody titers suggest clinical relapse. Prematurely stopping immunotherapy may lead to relapse, but prolonged AED intake is unnecessary.
Authors: Harry E Peery; Gregory S Day; Shannon Dunn; Marvin J Fritzler; Harald Prüss; Claire De Souza; Asif Doja; Karen Mossman; Lothar Resch; Chenjie Xia; Boris Sakic; Larry Belbeck; Warren G Foster Journal: Autoimmun Rev Date: 2012-03-11 Impact factor: 9.754
Authors: I Gabilondo; A Saiz; L Galán; V González; R Jadraque; L Sabater; A Sans; A Sempere; A Vela; F Villalobos; M Viñals; P Villoslada; F Graus Journal: Neurology Date: 2011-08-24 Impact factor: 9.910
Authors: Sarosh R Irani; Katarzyna Bera; Patrick Waters; Luigi Zuliani; Susan Maxwell; Michael S Zandi; Manuel A Friese; Ian Galea; Dimitri M Kullmann; David Beeson; Bethan Lang; Christian G Bien; Angela Vincent Journal: Brain Date: 2010-06 Impact factor: 13.501
Authors: Nicole R Florance; Rebecca L Davis; Christopher Lam; Christina Szperka; Lei Zhou; Saba Ahmad; Cynthia J Campen; Heather Moss; Nadja Peter; Amy J Gleichman; Carol A Glaser; David R Lynch; Myrna R Rosenfeld; Josep Dalmau Journal: Ann Neurol Date: 2009-07 Impact factor: 10.422
Authors: Guan Hongzhi; Kong Weize; Peng Bin; Huang Yan; Lu Qiang; Jing Yuan; Liu Qing; Shen Hang; Ren Haitao; Zhu Yicheng; Sun Dawei; Cui Liying Journal: Zhonghua Yi Xue Za Zhi Date: 2015-04-07
Authors: Heikki Laurikainen; Iina Isotupa; Mikko Nyman; Tuula Ilonen; Teija Nummelin; Raimo K R Salokangas; Jarmo Hietala Journal: BMC Psychiatry Date: 2019-05-10 Impact factor: 3.630